铂敏感复发性卵巢癌患者尼拉帕利剂量调整(RADAR)II期NEWTON试验
NEWTON试验评估尼拉帕利基于体重和血小板计数调整剂量(RADAR)策略的安全性。随机部分显示RADAR组3级及以上血小板减少发生率4.2%,标准剂量组41.7%,差异有统计学意义;RADAR组中位无进展生存期10.0个月。
要点
- RADAR策略降低3级及以上血小板减少发生率。
- 随机部分RADAR组与标准组发生率差异为-37.5%。
- RADAR组中位无进展生存期10.0个月。
核心结论
- 尼拉帕利RADAR剂量策略与较低的重度血小板减少发生率相关。
研究设计与样本
- II期NEWTON试验纳入铂敏感高级别浆液性或子宫内膜样卵巢癌、输卵管癌或原发性腹膜癌患者,以及具有胚系或体细胞BRCA突变的卵巢癌患者。
- 体重≥58且<77 kg或≥77 kg且血小板计数<150,000/μL者随机接受尼拉帕利200 mg(RADAR)或300 mg(标准);体重<58 kg者分配至200 mg(RADAR);体重≥77 kg且基线血小板≥150,000/μL者分配至300 mg(RADAR)。
- 随机部分48例,非随机分配至RADAR者34例,整个RADAR队列共58例。
主要发现
- 随机部分RADAR组3级及以上血小板减少发生率为4.2%,标准组为41.7%,差异为-37.5%(72%CI -49.2至-25.8,Z检验p=0.0044)。
- RADAR队列57例中6例发生3级及以上血小板减少(10.5%,70%CI 5.2-18.6)。
- 随机部分RADAR组和300 mg组中位无进展生存期分别为10.3个月和11.7个月;整个RADAR队列中位无进展生存期为10.0个月。
关键数值与推荐
- 主要终点为第3周期内3级及以上血小板减少。
- 对于分配至200 mg者,若第3周期内无血小板减少、严重中性粒细胞减少或贫血,考虑在第4周期剂量递增至300 mg。
临床怎么用
- 对于铂敏感复发性卵巢癌患者,可根据体重和基线血小板计数采用RADAR策略调整尼拉帕利起始剂量以降低重度血小板减少风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrospective analyses of niraparib trials showed that baseline platelets and weight were associated with occurrence of G ≥ 3 thrombocytopenia. A rational adjustment of dose to reduce adverse reactions (RADAR) strategy was never prospectively compared with standard dose. METHODS: NEWTON aimed to evaluate the safety of niraparib RADAR dosing strategy in pts with platinum-sensitive, high-grade serous and endometroid ovarian, fallopian tube, or primary peritoneal cancer, as well as in pts with ovarian cancer and a germline or somatic BRCA mutation, irrespective of histologic subtype. Pts with weight≥ 58 and < 77 kg, or ≥ 77 kg with platelet count < 150,000/μL were randomized to receive niraparib 200 mg (RADAR) or 300 mg (standard). Pts < 58 kg were assigned to 200 mg (RADAR), and pts ≥ 77 kg with baseline platelet count ≥ 150,000/μL were assigned to 300 mg (RADAR). For pts assigned to 200 mg, in the absence of thrombocytopenia, severe neutropenia or anemia within cycle 3, dose escalation to 300 mg was considered at cycle 4. The primary endpoint was G ≥ 3 thrombocytopenia within cycle 3. RESULTS: 48 pts were randomized to RADAR or standard dose (300 mg/day) and 34 pts were assigned to RADAR without randomization. A total of 58 pts was included in the entire RADAR cohort. In the randomized part, a lower G≥ 3 thrombocytopenia incidence was observed in the RADAR compared to standard arm (4.2%, vs 41.7%, corresponding to a difference of -37.5%, 72%CI -49.2; -25.8, Z-test p= 0.0044). In the RADAR cohort, 6 pts out of 57 had G≥ 3 thrombocytopenia (10.5%, 70% CI: 5.2-18.6;). Median PFS was 10.3 and 11.7 months in the randomized RADAR and 300 mg arms. The median PFS in the entire RADAR cohort was 10.0 months. CONCLUSIONS: Niraparib RADAR dosing is associated with a lower incidence of severe thrombocytopenia. CLINICALTRIALS: gov number: NCT03891576.
引用
- Colombo N, Parma G, Tasca G, et al. Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49). Eur J Cancer. 2026. PMID: 41950571. doi:10.1016/j.ejca.2026.116685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。